Bringing the fundamentals into focus…
Back to Syros Pharmaceuticals, Inc.
How Syros Pharmaceuticals, Inc. stacks up
SYRS · against 0 other Healthcare companies of similar size
Valuation
0/ 100
No other companies to compare with in this group.
Ranked #1 of 1
Bars: peers in each 10-point band of the valuation score1 peers with a valuation score of 0–9, including SYRS · Click a bar to see the companies
Why valuation scores 0?
Weighted metrics compared with all Healthcare companies.Mainly because of its earnings yield and EBITDA yield, which are weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -767500.0% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. EBITDA yield: -5616.5% vs peer median 4.0%
- Free cash flow yield is not reported, so it is left out of the score.
Metric by metric
Position: dot = SYRS, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | SYRS | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1 reported | -767500.0% | -767500.0% | — | — | 30% |
| EBITDA yieldHigher is better · 1 reported | -5616.5% | -5616.5% | — | — | 50% |
| Free cash flow yieldHigher is better · 0 reported | Not reported | — | — | — | 20% |
| Book yieldHigher is better · 1 reported | -103750.0% | -103750.0% | — | — | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by valuation score
Top 5 and the companies ranked around SYRS| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 0M USD | 0 | 1 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score